Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Total Current Assets
All assets expected to be converted to cash or used up within one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Total Current Assets · Q2 FY2026 · quarter ended Jun 2026
Total current assets rises 92.2% from a year ago
Total current assets stood at $991.73M at the end of Q2 FY2026, up 92.2% from a year earlier and down 7.6% from the prior quarter. Over 3 fiscal years it compounded at +69.6% a year.
Context
- Total current assets amounted to 74.2% of total assets at the end of Q2 FY2026, down 4.2 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +92.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 741.36M USD
- Year-over-year change
- +40.0%
- 3-year CAGR
- +69.6%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 741.36M | +40.0% |
| FY2024 | 2024-12-31 | 529.71M | +33.0% |
| FY2023 | 2023-12-31 | 398.41M | +162.0% |
| FY2022 | 2022-12-31 | 152.06M | — |
Total Current Assets vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +92.2% is the 4th highest of 10, against a peer median of +11.2%.
- Total current assets amounts to 74.2% of total assets for APGE, versus a peer median of 80.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥2.95B CNY | +99.8% | +21.6% | 74.3% |
| Sep 2026 | $1.14B USD | -7.8% | +4.3% | 68.1% | |
| Sep 2026 | $1.01B USD | +44.8% | +72.8% | 96.3% | |
| Jun 2026 | $991.73M USD | +92.2% | +69.6% | 74.2% | |
| Sep 2026 | $960.07M USD | +100.0% | -2.3% | 80.0% | |
| Jun 2026 | $914.04M USD | -11.6% | -3.2% | 85.0% | |
| Jun 2026 | $775.84M USD | +323.7% | +38.5% | 93.7% | |
IRONDisc Medicine, Inc. | Sep 2026 | $697.41M USD | +11.2% | +59.4% | 99.7% |
| Mar 2026 | $657M USD | -6.0% | +2.5% | 50.7% | |
| Mar 2026 | $348.68M USD | +0.3% | -5.6% | 54.3% | |
| Peer median (excluding APGE) | — | +11.2% | +4.3% | 80.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.